論文発表（業績）

No	Title（論文）	Author （著者）	Journal（掲載誌） Vol&Page（号数、ページ数） / Year （掲載年）	Pub Med ID
84	A pilot study on the safety and efficacy of neoadjuvant chemo‑adoptive immunotherapy for locally advanced rectal cancer	Yu Okazawa, Takashi Kamigak, Kiichi Sugimoto, Takeshi Yamada, Yoichiro Yoshida, Sachiko Okada, Hiroshi Ibe, Eri Oguma, Takuma Iwai, Akihisa Matsuda, Teppei Yamada, Suguru Hasegawa, Shigenori Goto, Rishu Takimoto, Kazuhiro Sakamoto	Oncology Letters January 15, 2024 101	38298433
83	Effects of adoptive T-cell immunotherapy on immune cell profiles and prognosis of patients with unresectable or recurrent cholangiocarcinoma	Kida A, Mizukoshi E, Kitahara M, Miyashita T, Goto S, Kamigaki T, Takimoto R, Asai J, Kakinoki K, Urabe T, Tomita K, Kaneko S.	International Journal of Cancer Sep 7. doi: 10.1002/ijc.34716. Online ahead of print.　/ 2023	37676069
82	Safety evaluation of immune-cell therapy for malignant tumor in the Cancer Immune-cell Therapy Evaluation Group (CITEG)	Takimoto R, Kamigaki T, Ito H, Saito M, Takizawa K, Soejima K, Yasuda H, Ohgino K, Terai H, Tomita K, Miura M, Mizukoshi E, Miyashita T, Nakamoto Y, Hayashi K, Miwa S, Kitahara M, Takeuchi A, Kimura H, Mochizuki T, Sugie H, Seino K, Yamada T, Takeuchi S, Makita K, Naitoh K, Yasumoto K, Yoshida Y, Inoue H, Kotake K, Ohshima K, Noda S, Okamoto M, Yoshimoto Y, Okada S, Ibe H,Oguma E, Goto S for theCITEG.	Cytotherapy Available online 22 July 2023　/ 2023	37486281
81	Efficacy of Adjuvant Immune-cell Therapy Combined With Systemic Therapy for Solid Tumors	Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E , Goto S	Anticancer Research 42: 4179-4187　/ 2022	35896218
80	Long-term, 25-year Survival Following Surgery and Immune Cell Therapy　Combined with Chemotherapy for HER2-Positive Metastatic Breast Cancer: A Case Report	Shindo G, Endo T, Miyamoto Y, Onda M, Kimura M, Takimoto R,Ibe H, Goto S.	British Journal of Cancer Research 4(2): 491 – 495　/ 2021 doi: 10.31488/bjcr.167
79	Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy	Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E , Goto S	Anticancer Research 41:4133-4141 / 2021	34281884
78	Esophageal cancer responsive to the combination of immune cell therapy and low‑dose nivolumab: two case reports	Takimoto R, Kamigaki T, Gotoda T, Takahashi T, Okada S, Ibe H, Oguma E , Goto S	Journal of Medical Case Reports 15, Article number: 191 / 2021	33827668
77	Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer.	Kumai T, Mizukoshi E, Hashiba T, Nakagawa H, Kitahara M, Miyashita T, Mochizuki T, Goto S, Kamigaki T, Takimoto R, Yamashita T, Sakai Y, Yamashita T, Honda M, Tomita K, Kaneko S	CYTOTHERAPY Feb;23(2):137-145 / 2020	32907781
76	Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy	Yamada T, Yoshida Y, Maeda T, Yoshimatsu G, Aisu N,Yamashita K, Komono A, Kajitani R, Matsumoto Y, Nagano H, Naitoh K, Yasumoto K, Takimoto R, Kamigaki T, Goto S, Yoshimura F, Sakata N, Kodama S, Hasegawa S.	Anticancer Research 40: 4763-4771 / 2020	32727803
75	Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix	Goto S, Terao Y, Kamigaki T, Takimoto R, Naitoh K, Makita K, Yasumoto K, Okada S, Takizawa K, Yokomichi N, Suzuki N, Takeda S.	Anticancer Research 40: 4741-4748 / 2020	32727800
74	Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy A Retrospective Study	Takimoto R, Kamigaki T, Okada S, HIROSHI Ibe H, Oguma E, Naitoh K, Makita K, Yasumoto K, Goto S.	Anticancer Research 40: 4729-4740 / 2020	32727799
73	Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer	Miura M, Mizukoshi E, Hashiba T, Kitahara M, Miyashita T, Mochizuki T, Goto S, Kamigaki T, Takimoto R, Yamashita T, Sakai Y, Yamashita T, Honda M, Kaneko S.	Cancer Med 9(14):4907-4917 / 2020	32529780
72	Identification of prognostic factors for gdT cell immunotherapy in patients with solid tumor	Takimoto R, Miyashita T,Mizukoshi E, Kamigaki T, Okada S, Ibe H, Oguma E, Naitoh K, Yasumoto K, Makita K, Tomita K, Goto S.	CYTOTHERAPY Jun;22(6):329-336 / 2020	32303429
71	Prognostic Factors for Colorectal Cancer Patients Treated With Combination of Immune-cell Therapy and First-line Chemotherapy: A Retrospective Study	Takimoto R, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Makita K, Goto S.	Anticancer Research 39: 4525-4532 / 2019	31366555
70	Significant clinical response of advanced colorectal cancer to combination therapy involving capecitabine and adoptive cell transfer therapy: a case report	Shuchun Li, Junjun Ma, Xizhou Hong, Minhua Zheng, Shigenori Goto, Rishu Takimoto,Takashi Kamigaki, Lu Zang	Translational Cancer Research 8(2):693-698 / 2019
69	4章　原発性肺癌治療の実際　薬物療法「その他の免疫療法」	後藤重則	呼吸器疾患診断治療アプローチ　3；4章　230-234 / 2018
68	がん免疫療法の新展開　ー　「知らない」ではすまない今のトレンド【がん免疫療法の分類と作用機序】　免疫細胞療法とは何か	後藤重則、神垣隆、瀧澤憲	臨床婦人科産科第72巻　第6号 / 2018
67	Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy	Makita K, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Takimoto R, Goto S.	Anticancer Research 38 (7) 4353-4360 / 2018	29970573
66	Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial	Yoshiki Hirooka, Hiroki Kawashima, Eizaburo Ohno, Takuya Ishikawa, Takashi Kamigaki, Shigenori Goto, Masashi Takahara, and Hidemi Goto	Oncotarget Dec 5;9(2):2838-2847. / 2017	29416816
65	Prospective pilot study of adoptive immunotherapy with autologous αβT cells for five cases of advanced and/or recurrent esophageal squamous cell carcinoma	Nanami T, Shimada H,Yajima S, Oshima Y, Suzuki T, Shiratori F, Sumazaki M, Otsuka S,Kamigaki T, Goto S, Kaneko H.	Esophagus October 2017, Volume 14, Issue 4, pp 303–308 / 2017
64	Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma	Kanemura Y, Sumida M, Okita Y, Yoshida E, Yamamoto A, Kanematsu D, Handa Y, Fukusumi H, Inazawa Y, Takada A, Nonaka M, Nakajima S, Mori K, Goto S, Kamigaki T, Shofuda T, Moriuchi S, Yamasaki M	Anticancer Research Jul;37(7):3921-3932. / 2017	28668896
63	Clinical Study on the Medical Value of Combination Therapy Involving Adoptive Immunotherapy and Chemotherapy for Stage IV Colorectal Cancer (COMVI Study)	Yoshida Y, Naito M, Yamada T, Aisu N, Kojima D, Mera T, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Goto S, Kodama S, Yamashita Y, Hasegawa S	Anticancer Research Jul;37(7):3941-3946. / 2017	28668898
62	Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells	Ishi F, Yoshida Y, Yamauchi Y, Aisu N, Kojima D, Mera T, Kato D, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Goto S, Hamada Y, Nimura S, Kodama S, Hasegawa S	Anticancer Research Jul;37(7):3933-3939. / 2017	28668897
61	Efficacy of Adoptive Immune-cell Therapy in Patients with Advanced Gastric Cancer: A Retrospective Study	Takimoto R, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Makita K, Goto S	Anticancer Research Jul;37(7):3947-3954. / 2017	28668899
60	免疫細胞療法の現状と今後の展開	神垣隆、阿曽沼元博、後藤重則	映像MEDICAL Vol.49 No.4 / 2017
59	免疫細胞療法の現状と展望	後藤重則、瀧本理修、牧田香理、内藤恵子、神垣隆	呼吸器内科 31(4):323-330, / 2017
58	がん免疫治療　-がん完治に向けての新たな治療法の探索- II.　各論　癌免疫細胞療法腫瘍ライセートを用いた固形腫瘍に対する樹状細胞ワクチン療法	神垣隆、高原将司、照屋剛、城間寛、善本隆之、後藤重則	日本臨床 75巻　2号 / 2017
57	Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research.	Inoo K, Inagaki R, Fujiwara K, Sasawatari S, Kamigaki T, Nakagawa S, Okada N.	Mol Ther Oncolytics. Nov 16;3:16024. / 2016	27909701
56	Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer.	Yoshida Y, Naito M, Yamada T, Aisu N, Daibo K, Mera T, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Goto S, Yamashita Y, Hasegawa S.	Anticancer Research Jul;36(7):3741-6. / 2016	27354648
55	Therapeutic Potential of Zoledronate-Activated Autologous γδT Cells in Atopic Dermatitis.	Kamigaki T,Naitoh K, Goto S.	J Investig Allergol Clin Immunol. Oct;26(5):336-338. / 2016	27763869
54	Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer Cells	Naitoh K, Kamigaki T, Matsuda E, Ibe H, Okada S, Oguma E, Kinoshita Y, Takimoto R, Makita K, Ogasawara S, Goto S.	Anticancer Research 36(7):3715-3724 / 2016	27354645
53	がん免疫治療	神垣隆、内藤恵子、牧田香理、瀧本理修、後藤重則	腎臓内科・泌尿器科 3(3):294-302 / 2016
52	T細胞輸注療法　～肺癌・膵癌を中心として～	神垣隆、後藤重則	書籍「がん」2016年2月第8章　第3節 / 2016
51	免疫細胞療法と肺がん	後藤重則、内藤恵子、神垣隆	呼吸器内科 28(6):463-468 / 2015
50	Improvement of Impaired Immunological Status of Patients with Various Types of Advanced Cancers by Autologous Immune Cell Therapy	Kamigaki T, Ibe H, Okada S, Matsuda E, Tanaka M,Oguma E, Kinoshita Y,Ogasawara S,Ono A,Makita K,Naitoh K,Goto S.	Anticancer Research 35(8):4535-4543 / 2015	26168498
49	これから期待される肺癌診断と治療「免疫細胞治療」	後藤重則、神垣隆、内藤恵子	呼吸器内科 26(6);421-426 / 2014
48	免疫細胞療法の最新動向と今後の展開	神垣隆、後藤重則	腫瘍内科第13巻　第5号 / 2014
47	Prospective Evaluation of Safety of Immune-cell Therapy for Patients with Various Types of Advanced Cancer．	Kamigaki T, Matsuda E, Okada S, Naitoh K, Kondo T, Ibe H, Maekawa R and Goto S.	Anticancer Research 34(8):4601-7. / 2014	25075106
46	食道癌に対する免疫療法の現状と展望	神垣隆、内藤恵子、後藤重則	Pharma Medica Vol32 No.7. / 2014
45	婦人科がんに対する免疫細胞療法の実際	瀧澤憲、後藤重則	産科と婦人科 Vol.81　No.2. / 2014
44	Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy.	Noguchi A, Kaneko T, Naitoh K, Saito M, Iwai K, Maekawa R, Kamigaki T, Goto S.	International Immunopharmacology 18(1):90-97. / 2014	24269583
43	免疫療法：特に肺癌に対する免疫療法の可能性	安元公正、宗哲哉、能勢直弘、内藤恵子、富山舞、前川隆司	日本臨床環境医学第22巻　第1号 / 2013
42	Zoledronate-pulsed dendritic cell-based anticancer vaccines．	Kamigaki T, Takahara M, Maekawa R, Goto S.	Oncolmmunology 2(9):e25636. / 2013	24319636
41	Is the CD4/CD8 Ratio an Effective Indicator for Clinical Estimation of Adoptive Immunotherapy for Cancer Treatment?	Shindo G, Endo T, Onda M, Goto S, Miyamoto Y, Kaneko T.	Cancer Therapy 4, 1382-1390. / 2013
40	Immunotherapy of Autologous Tumor Lysate-loaded Dendritic Cell Vaccines by a Closed-flow Electroporation System for Solid Tumors.	Kamigaki T, Kaneko T, Naitoh K, Takahara M, Kondo T, Ibe H, Matsuda E, Maekawa R, Goto S.	Anticancer Research 33(7):2971-6. / 2013	23780988
39	A patient with Scirrhous Stomach Cancer treated with Combination of Hyperthermotherapy and 5-Aminolevulinic acid (ALA) .	Saito M, Yano K, Kamigaki T, Goto S.	Anticancer Research 33(7):2957-63. / 2013	23780986
38	国際的にみたがん免疫細胞治療の研究開発の現状と展望	後藤重則、阿曽沼元博	医薬品医療機器レギュラトリーサイエンス 44(6), 458-463. / 2013
37	Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study.	Iwai K, Soejima K, Kudoh S, Umezato Y, Kaneko T, Yoshimori K, Tokuda H, Yamaguchi T, Mizoo A, Setoguchi Y, Kamigaki T, Fujimoto K, Goto S.	Cancer Immunology, Immunotherapy 61:1781-1790. / 2012	22422103
36	Immuno-cell therapy with antecedent surgery has superior actuarial survival to immuno-cell therapy without antecedent surgery for advanced cancers.	Sindo G, Endo T, Onda M, Miyamoto Y, Kaneko,T and Goto S.	Cancer Immunology, Immunotherapy 60(10):1397-1403. / 2011	21638124
35	Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.	Noguchi A, Kaneko T, Kamigaki T, Fujimoto K, Ozawa M, Saito M, Ariyoshi N, Goto S.	Cytotherapy 13(1):92-7. / 2011	20831354
34	Lymphokine-activated killer cell therapy combined with high-dose glucocorticoid showed clinical efficacy towards advanced lung carcinoma.	Kato M, Goto S, Soma G.	Anticancer Research 30(8):3125-8. / 2010	20871030
33	A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells.	Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, Takamoto S, Kakimi K.	Eur J Cardiothorac Surg 37(5):1191-7. / 2010	20137969
32	切除不能局所進行膵癌に対するゲムシタビンと免疫細胞療法の併用治療	廣岡芳樹, 伊藤彰浩, 川嶋啓揮, 原和生, 野々垣浩二, 春日井俊史, 大野栄三郎, 石川卓哉, 松原浩, 石上雅敏, 片野義明, 大宮直木, 丹羽康正, 山本晃士, 金子亨, 贄田美江, 横川潔, 後藤秀実	膵臓 24(5):632-4. / 2009
31	切除不能局所進行膵癌に対するEUS下樹状細胞局注療法	廣岡芳樹、伊藤彰浩、川嶋啓揮、大野栄三郎、石川卓哉、松原浩、伊藤裕也、中村陽介、中村正直、宮原良二、大宮直木、石上雅敏、片野義明、金子亨、後藤重則、後藤秀実	胆と膵 30: 1257-61. / 2009
30	患者背景および腫瘍細胞の性質による免疫細胞療法の選択、個別化	後藤重則、金子亨、明山燿久、藤本勝洋、伊藤克礼、佐藤志保、野口敦崇、神宮司英雅	Biotherapy 23: 317-24. / 2009
29	EUS下穿刺術を応用した樹状細胞注入療法	廣岡芳樹、伊藤彰浩、川嶋啓揮、大野栄三朗、石川卓哉、松原浩、伊藤裕也、中村正直、宮原良二、大宮直木、丹羽泰正、後藤秀美、原和生、金子亨、後藤重則	消化器内視鏡 21: 958-63. / 2009
28	Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.	Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T, Goto S, Yokokawa K, Suzuki K.	Exp Hematol 37(8):956-68. / 2009	19409955
27	A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer.	Hirooka Y, Itoh A, Kawashima H, Hara K, Nonogaki K, Kasugai T, Ohno E, Ishikawa T, Matsubara H, Ishigami M, Katano Y, Ohmiya N, Niwa Y, Yamamoto K, Kaneko T, Nieda M, Yokokawa K, Goto H.	Pancreas 38(3):e69-74. / 2009	19276867
26	原発性肺癌に対する活性化自己リンパ球移入療法の経験-手術不能非小細胞肺癌での遠隔成績を中心として-	岩井和郎、後藤重則、金子亨、加藤昭、明山燿久、藤本勝洋	Biotherapy 23: 28-36. / 2009
25	化学療法・放射線療法・免疫細胞療法からなる集学治療による左肺腺癌完全寛解の1例	加藤昭、明山燿久、和田洋巳、池田剛司、田中佳代	Biotherapy 22: 351-6. / 2008
24	下咽頭癌再発、既照射例に、少線量放射線、低用量化学療法、免疫細胞療法からなる集学治療による再発腫瘍寛解の1例	加藤昭	Biotherapy 20: 613-8. / 2006
23	A Case of Recurrent Ovarian Cancer Successfully Treated with Adoptive Immunotherapy and Lentinan.	Fujimoto K, Tomonaga M, Goto S.	Anticancer Research 26: 4015-8. / 2006	17195451
22	The Therapeutic Potential of Immuno-cell Therapy of Cancer in Combination with Aminobisphosphonates.	Goto S, Noguchi A, Jinguji H, Takahara M.	Anticancer Research 26: 3989-96. / 2006	17195447
21	切除不能膵癌に、gemcitabine・少線量放射線・CD3-LAK による集学的治療が有効であった1 例	加藤昭、明山燿久、河合公三	Biotherapy 20: 87-90. / 2006
20	免疫細胞療法の現状と問題点	後藤重則	臨床放射線 50：1276-8. / 2005
19	免疫細胞療法の現状：普及医療としての活性化自己リンパ球療法を中心として	江川滉二	BCG・BRM療法研究会会誌 28：9-13. / 2005
18	Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma.	Goto S,Kaneko T, Miyamoto Y, Eriguchi M, Kato A, Akeyama T, Fujimoto K, Tomonaga M, Egawa K.	Anticancer Research 25(6A):3741-6. / 2005	16302734
17	Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer.	Kaneko T, Goto S, Kato A, Akeyama A, Tomonaga M, Fujimoto K, Miyamoto Y, Eriguchi M, Egawa K.	Anticancer Research 25(6A):3709-14. / 2005	16302730
16	高齢者癌の治療を語る　(4名の医師による高齢者の癌治療に関してのRound Table Discussion)	畠清彦、江川滉二、小口正彦、武藤徹一郎	老年医学 42; 1657-1672. / 2004
15	高齢者に対する免疫療法：免疫細胞療法を中心として	江川滉二	老年医学 42; 1643-7. / 2004
14	免疫細胞療法　Immuno-cell Therapy	後藤重則, 金子亨, 江川滉二	日本補完代替医療学会雑誌 1(1)85-93. / 2004
13	A Report of Three Patients Treated with Immunocell Therapy with Imatinib Mesylate.	Kaneko T, Goto S, Kushima Y, Miyamoto Y, Eriguchi M, Nieda M, Egawa K.	Anticancer Research 24; 3303- 9. / 2004	15515425
12	Immuno-cell therapy of cancer in Japan.	Kohji Egawa	Anticancer Research 24(5C):3321-6. / 2004	15515427
11	Mature dendritic cells are superior to immature dendritic cells in expanding antigen-specific naïve and memory CD8+T cells.	Tomiyama M, akahara M, Egawa K, Nieda M.	Anticancer Research 24(5C) 3327-33. / 2004	15515428
10	Tumor cell-specific transcription of a murine histocompatibility class Ib Q5 gene.	Noguchi K, Kuwata E, Goto S, Egawa K.	Anticancer Research 24(5C) 3379-86. / 2004	15515435
9	Detection of anti-HLA-F antibodies in sera from cancer cancer patients.	Noguchi K, Isogai M, Kuwata E, Noguchi A, Goto S, Egawa K．	Anticancer Research 24(5C) 3387-92. / 2004	15515436
8	On the Safety Assurance of Cell Processing Carried out in Medical Institutions for Autologous Immuno-cell Therapy.	Kohji Egawa	HUMAN CELL 17(1) 1- 6. / 2004	15369131
7	特集【免疫を高める方法】健康と免疫	後藤重則	健康創造研究会誌　別冊 2(2)81-86. / 2003
6	特集【免疫を高める方法】医療における免疫の増強	金子亨	健康創造研究会誌　別冊 2(2)113-22. / 2003
5	第1特集　免疫細胞療法の躍進　概論　免疫細胞療法の現状と展望	江川滉二	Bioベンチャー　別冊 1(2)16-8. / 2003
4	第1特集　免疫細胞療法の躍進　瀬田クリニックグループでの免疫細胞療法	後藤重則	Bioベンチャー　別冊 1(2)28-31. / 2003
3	特集【癌の免疫学－癌免疫療法の理論と臨床－】　がんの免疫細胞療法：活性化自己リンパ球療法を中心として	江川滉二	呼吸 22(12)1190-5. / 2003
2	Ex vivo enhancement of antigen-presenting function of dendritic cells and its application for DC-based immunotherapy.	Nieda M, Tomiyama M, Egawa K.	HUMAN CELL 16(4)199-204. / 2003	15147040
1	Clinical Benefit of Non-toxic Therapy in Patients with Advanced Cancer (Opinion).	Goto S, Shirotani N, Hatakeyama M, Tagami C, Arakawa H, Kuwata E, Noguchi K, Egawa K.	Anticancer Research 22; 2461-4. / 2002	12174944